MedTrace Logo

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

NCT04713254 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-04-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of repeated doses of the drug Lu AG06466 on the exposure of metoprolol, midazolam and bupropion

Conditions

  • Healthy

Interventions

DRUG

Lu AG06466

10, 20, 30 mg/day oral capsules on Day 5-18

OTHER

Midazolam

4 mg syrup, oral single dose on Day 1 and Day 15

OTHER

Metoprolol

100 mg tablets, oral single dose on Day 1 and Day 15

OTHER

Bupropion

100 mg tablets, oral single dose on Day 3 and Day 17

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-08
Primary Completion
2021-04-09
Completion
2021-04-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04713254 on ClinicalTrials.gov